CymaBay Therapeutics, Inc. 0I5P.L Stock
CymaBay Therapeutics, Inc. Price Chart
CymaBay Therapeutics, Inc. 0I5P.L Financial and Trading Overview
| CymaBay Therapeutics, Inc. stock price | 32.48 USD |
| Previous Close | 9.62 USD |
| Open | 0 USD |
| Bid | 0 USD x N/A |
| Ask | 0 USD x N/A |
| Day's Range | 0 - 0 USD |
| 52 Week Range | 0 - 10.87 USD |
| Volume | 7.64K USD |
| Avg. Volume | 1.51K USD |
| Market Cap | 6.09M USD |
| Beta (5Y Monthly) | 0.269014 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | 0 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
0I5P.L Valuation Measures
| Enterprise Value | 751.58M USD |
| Trailing P/E | N/A |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 8.561682 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | -7.933 |
Trading Information
CymaBay Therapeutics, Inc. Stock Price History
| Beta (5Y Monthly) | 0.269014 |
| 52-Week Change | 294.02% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 10.87 USD |
| 52 Week Low | 0 USD |
| 50-Day Moving Average | 9.5 USD |
| 200-Day Moving Average | 6.64 USD |
0I5P.L Share Statistics
| Avg. Volume (3 month) | 1.51K USD |
| Avg. Daily Volume (10-Days) | 1.11K USD |
| Shares Outstanding | 59.44M |
| Float | 86.86M |
| Short Ratio | N/A |
| % Held by Insiders | 0.31% |
| % Held by Institutions | 74.38% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | N/A |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -26.76% |
| Return on Equity (ttm) | -101.15% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | -41635000 USD |
| EBITDA | -94744000 USD |
| Net Income Avi to Common (ttm) | -107010000 USD |
| Diluted EPS (ttm) | -1.323 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 236.36M USD |
| Total Cash Per Share (mrq) | 2.42 USD |
| Total Debt (mrq) | 94.63M USD |
| Total Debt/Equity (mrq) | 90.83 USD |
| Current Ratio (mrq) | 5.22 |
| Book Value Per Share (mrq) | 1.07 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -52287000 USD |
| Levered Free Cash Flow (ttm) | -28473124 USD |
Profile of CymaBay Therapeutics, Inc.
| Country | United Kingdom |
| State | CA |
| City | Newark |
| Address | 7575 Gateway Boulevard |
| ZIP | 94560 |
| Phone | 510 293 8800 |
| Website | https://www.cymabay.com |
| Industry | |
| Sector(s) | |
| Full Time Employees | 60 |
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta for the treatments of autoimmune liver disease, primary biliary cholangitis (PBC). The company also develops MBX-2982 for the disease/condition of hypoglycemia in type 1 diabetics. It has a license agreement with ABW Cyclops SPV LP to support development of seladelpar for the treatment of PBC; and holds a worldwide license from Janssen Pharmaceuticals, Inc. to research, develop, and commercialize compounds with activity against an undisclosed metabolic disease target. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Newark, California.
Q&A For CymaBay Therapeutics, Inc. Stock
What is a current 0I5P.L stock price?
CymaBay Therapeutics, Inc. 0I5P.L stock price today per share is 32.48 USD.
How to purchase CymaBay Therapeutics, Inc. stock?
You can buy 0I5P.L shares on the LSE exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for CymaBay Therapeutics, Inc.?
The stock symbol or ticker of CymaBay Therapeutics, Inc. is 0I5P.L.
How many shares does CymaBay Therapeutics, Inc. have in circulation?
The max supply of CymaBay Therapeutics, Inc. shares is 664.4K.
What is CymaBay Therapeutics, Inc. Price to Earnings Ratio (PE Ratio)?
CymaBay Therapeutics, Inc. PE Ratio is 0.00000000 now.
What was CymaBay Therapeutics, Inc. earnings per share over the trailing 12 months (TTM)?
CymaBay Therapeutics, Inc. EPS is 0 USD over the trailing 12 months.